We identified a novel JSRP1 intergenic region-<i>ALK</i> fusion as a carcinogenic mutation that responds to alectinib, thereby expanding the spectrum of <i>ALK</i> fusion partners in <i>ALK</i> + NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.